Research programme: anti-respiratory virus antibodies- GlaxoSmithKline/Vir Biotechnology
Alternative Names: Anti-respiratory virus antibodies- GlaxoSmithKline/Vir BiotechnologyLatest Information Update: 23 Feb 2021
At a glance
- Originator GlaxoSmithKline; Vir Biotechnology
- Developer GSK; Vir Biotechnology
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Influenza virus infections; Respiratory tract infections
Most Recent Events
- 17 Feb 2021 Vir Biotechnolgy and GlaxoSmithKline expands collaboration agreement to discover and develop monoclonal antibodies for Influenza virus infections and Respiratory tract infections
- 17 Feb 2021 Early research in Respiratory tract infections (Prevention) in United Kingdom, USA (Parenteral)
- 17 Feb 2021 Early research in Respiratory tract infections in United Kingdom, USA (Parenteral)